HIBADH knockout Jurkat polyclonal cells are a CRISPR/Cas9-edited polyclonal population derived from Jurkat T lymphoblasts, providing a loss-of-function model for valine catabolism and mitochondrial studies. This polyclonal product contains targeted HIBADH disruptions across a mixed cell pool, enabling experiments in a non-clonal context that retains population diversity. CRISPR/Cas9 editing introduces gene-inactivating mutations without clonal isolation.
Jurkat cells, originally from an acute T cell leukemia, are a widely used T lymphocyte model for signal transduction, apoptosis, and immune activation research. These suspension-adapted cells proliferate rapidly and express key components of the T cell receptor pathway, making them an ideal host for investigating metabolic pathways in immune cells. Their extensive characterization in apoptosis and metabolic studies provides a strong foundation for analyzing HIBADH function in T cell biology.
HIBADH is a mitochondrial enzyme that catalyzes the NAD+-dependent oxidation of 3-hydroxyisobutyrate to methylmalonate semialdehyde, a critical step in valine degradation. Located downstream of the BCKDH complex, this reaction channels carbon units into propanoate metabolism and the TCA cycle via succinyl-CoA. Enzyme activity is regulated by PPAR??, PGC-1??, and mTORC1 signaling and relies on NAD+ as a cofactor. Methylmalonate semialdehyde is subsequently processed by ALDH6A1 to propionyl-CoA, highlighting the interplay with mitochondrial energy pathways. HIBADH disruption therefore blocks this metabolic route, leading to 3-hydroxyisobutyrate accumulation and mitochondrial dysfunction.
In Jurkat T cells, HIBADH knockout offers a powerful model to explore how valine catabolism influences T cell metabolic reprogramming, survival, and activation. T cells dynamically shift their metabolism upon stimulation, and branched-chain amino acid oxidation may supply key intermediates for mitochondrial respiration and biosynthesis. Loss of HIBADH can impair ATP production, alter the balance between glycolysis and oxidative phosphorylation, and modulate apoptosis sensitivity. This model is therefore highly relevant for studying amino acid metabolism in immune cell function and for modeling mitochondrial disorders such as 3-hydroxyisobutyric aciduria.
These polyclonal knockout cells are suited for a range of molecular and functional assays. Gene disruption can be verified by Western blotting, RT-qPCR, and Sanger sequencing of the HIBADH locus. Metabolic blockade is confirmed by LC-MS-based quantitation of 3-hydroxyisobutyrate, while mitochondrial respiration and glycolytic activity are assessed using Seahorse flux analysis. ATP levels can be measured as an indicator of energy status, and immunology-specific studies can employ Annexin V apoptosis assays and CD69 activation markers. The product is also applicable to pharmacological screens targeting branched-chain amino acid metabolism. For further information, please contact Ascent Research.
